{"id":"W4399926566","doi":"10.1016/j.esmoop.2024.103539","title":"39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Daiichi Sankyo Europe; LEO Pharma; Eisai; Cilag; Novocure; Astellas Pharma; Clovis Oncology; Amgen; Pfizer; MorphoSys; PharmaMar; Mersana Therapeutics; Fujirebio US; AstraZeneca; Eli Lilly and Company","keywords":"Pembrolizumab; Lenvatinib; Medicine; Oncology; Chemotherapy; Internal medicine; Endometrial cancer; Gynecology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006992514,0.0007144776,0.001557661,0.0004448839,0.0003214965,0.0003042118,0.0007460885,0.0002244916,0.01114288],"category_scores_gemma":[0.0005010905,0.000487349,0.000417405,0.001802977,0.00008921005,0.0004272877,0.0002050522,0.000498878,0.0001495625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006606636,"about_ca_system_score_gemma":0.0007786781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003801757,"about_ca_topic_score_gemma":0.00136315,"domain_scores_codex":[0.9959537,0.0001166911,0.0009912167,0.001305437,0.0008107552,0.0008222438],"domain_scores_gemma":[0.9972084,0.001035295,0.0002444429,0.0007934225,0.0002781429,0.0004402991],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2004428,0.007329215,0.0004330926,0.000255307,0.001973944,0.0001580882,0.001123746,0.000008077837,0.0003466922,0.0001083795,0.0069835,0.7808372],"study_design_scores_gemma":[0.3205167,0.02390058,0.0007055554,0.0005416266,0.0005123253,0.00002659397,0.0002306914,0.0001710947,0.01125598,0.0003116013,0.6411821,0.0006451218],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9399029,0.01125999,0.0002065868,0.009225388,0.005644167,0.02499916,0.0007396369,0.0005245986,0.00749755],"genre_scores_gemma":[0.9569085,0.0114581,0.0006084593,0.002507247,0.002853069,0.00729333,0.0004962715,0.0002322491,0.01764274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7801921,"threshold_uncertainty_score":0.9997578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08448183385298305,"score_gpt":0.4378377915686064,"score_spread":0.3533559577156233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}